<?xml version="1.0" encoding="UTF-8"?>
<p>In Normandy, 87.9% of serum samples were above 85 mm
 <sup>2</sup> (175.9 mm
 <sup>2</sup>; 
 <italic>n</italic> = 1614; 
 <xref ref-type="fig" rid="vaccines-07-00174-f002">Figure 2</xref>), including 62.3% of samples ≥154 mm
 <sup>2</sup> (195.2 ± 28.3 mm
 <sup>2</sup>; 
 <italic>n</italic> = 1144). The SRH antibody analysis of 1837 serum samples by categories showed that 74.4%, 95.2%, 96.4% and 86.5% of samples were ≥85 mm
 <sup>2</sup> for the sale, breeding, exportation and diagnosis categories, respectively (
 <xref ref-type="fig" rid="vaccines-07-00174-f002">Figure 2</xref>A), with a statistically significant difference between categories (
 <italic>p</italic>-value &lt; 0.00001). The frequency of serum samples reaching at least the clinical protection threshold for the sale category was significantly lower than that of other categories (breeding, exportation and diagnosis; 
 <italic>p</italic>-values ≤ 0.00001, 0.00001 and &lt;0.0001, respectively). After the exclusion of samples from horses born in 2016 and 2017 for the sale category, the frequency of serum samples with SRH antibody titers above 85 mm
 <sup>2</sup> increased significantly from 74.4% to 94.9% (
 <italic>p</italic>-value &lt; 0.00001; 
 <xref ref-type="fig" rid="vaccines-07-00174-f003">Figure 3</xref>).
</p>
